GENE ONLINE|News &
10 Top Gene Therapy Companies in 2021
Three years ago, the FDA granted landmark approval to the first in vivo gene therapy for treating an inherited eye disease. Luxturna, an AAV2 based gene therapy developed by Spark Therapeutics, bagged regulatory win to treat this eye disease called Leber congenital amaurosis. Since then, the agency has approved Zolgensma, a spinal muscular atrophy treatment, and has given green light to dozens of small and big biotechs to start clinical trials for their gene therapies.
GO Prime with only $1.49 now
LATEST
David vs. Goliath: Taiwan’s PGI Wins $23M Settlement in Sequencing Patent Dispute with U.S. PacBio
2026-03-13
Gut Microbiome Composition Predicts Long-term Cardiometabolic Health Outcomes in Diverse Urban Populations
2026-03-12
NVIDIA Ahead of GTC 2026: Markets Focus on Data Center Strength, PC Expansion, and the Next Technical Breakout
2026-03-12
Global and APAC Biopharma Watch: Capital Raising, Clinical Expansion, and Industry Moves in Focus
2026-03-12
EVENT
2026-04-09
4th Cell & Gene Therapy Innovation & Access Congress: Asia (Media Partnership)
Seoul, South Korea
2026-04-17
AACR Annual Meeting 2026 (Cancer Research & Early-Stage Breakthroughs)
San Diego, California
